← back to search

Laura C. Cappelli

Apple (Israel) · US
Area of research
Oncology · Rheumatology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Rheumatoid Arthritis Research and Therapies, Colorectal Cancer Treatments and Studies, and Chronic Lymphocytic Leukemia Research.
h-index
37
citations
7,541
works
122
NIH funding
primary concept
Medicine
email

Recent publications

Immune-related encephalitis after immune checkpoint inhibitor therapy
The Oncologist 2024cited by 25position: middledoi
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Journal of Translational Medicine 2024cited by 9position: middledoi
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Arthritis Care & Research 2023cited by 182position: middledoi
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Journal for ImmunoTherapy of Cancer 2023cited by 133position: lastdoi
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Annals of the Rheumatic Diseases 2023cited by 71position: lastdoi
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Arthritis & Rheumatology 2023cited by 62position: middledoi
Treatment of rheumatic adverse events of cancer immunotherapy
Best Practice & Research Clinical Rheumatology 2022cited by 22position: lastdoi
Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey
Rheumatology Advances in Practice 2022cited by 19position: lastdoi
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Arthritis Care & Research 2021cited by 1,257position: middledoi
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Arthritis & Rheumatology 2021cited by 1,020position: middledoi
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer 2021cited by 804position: middledoi
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
ACR Open Rheumatology 2021cited by 138position: middledoi
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Journal of Clinical Oncology 2021cited by 29position: middledoi
Checkpoint Inhibitor–Associated Arthritis
JCR Journal of Clinical Rheumatology 2020cited by 74position: middledoi
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Annals of the Rheumatic Diseases 2019cited by 225position: lastdoi
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Journal of Clinical Investigation 2019cited by 197position: middledoi
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
The Oncologist 2019cited by 176position: middledoi
2019 American College of Rheumatology Recommended Patient‐Reported Functional Status Assessment Measures in Rheumatoid Arthritis
Arthritis Care & Research 2019cited by 50position: middledoi
Rheumatic immune-related adverse events from cancer immunotherapy
Nature Reviews Rheumatology 2018cited by 227position: lastdoi
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
Seminars in Arthritis and Rheumatism 2018cited by 157position: firstdoi
Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Arthritis Care & Research 2016cited by 394position: firstdoi
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Annals of the Rheumatic Diseases 2016cited by 391position: firstdoi
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Rheumatic Disease Clinics of North America 2016cited by 118position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Clifton O. Bingham · Johns Hopkins University8 papers (2016–2023)Jarushka Naidoo · Johns Hopkins Bayview Medical Center6 papers (2016–2024)Ami A. Shah · Johns Hopkins University6 papers (2016–2023)Evan J. Lipson · Smilow Cancer Hospital6 papers (2016–2024)Julie R. Brahmer · Bloomberg (United States)6 papers (2016–2024)Patrick M. Forde · Johns Hopkins University3 papers (2018–2024)Pankti Reid · University of Chicago3 papers (2021–2023)Dung T. Le · Johns Hopkins University3 papers (2016–2019)Blake M. Warner · National Institutes of Health2 papers (2019–2021)Nilasha Ghosh · Hospital for Special Surgery2 papers (2020–2023)Anna Kristina Gutierrez · Makati Medical Center2 papers (2016–2016)Karmela K Chan · Hospital for Special Surgery2 papers (2020–2023)María E. Suarez‐Almazor · The University of Texas MD Anderson Cancer Center2 papers (2021–2023) · 2 papers (2021–2023)Anne R. Bass · Hospital for Special Surgery2 papers (2020–2023)Cassandra Calabrese · Case Western Reserve University2 papers (2018–2023)Alan N. Baer · Johns Hopkins University2 papers (2016–2019)Elad Sharon · Harvard University2 papers (2021–2023) · 1 papers (2019–2019)John-William Sidhom · NewYork–Presbyterian Hospital1 papers (2024–2024)